Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Raises $7M Through Malaysian Private Placement; Loan Agreement

Premium

This story has been updated from a previous version.

WaferGen Biosystems has raised $7 million in capital through a $5 million private placement by its Malaysian subsidiary and a $2 million loan agreement with Oxford Finance, the company said this week.

As part of the private placement, WaferGen's Malaysian subsidiary signed a purchase agreement with previous investor Malaysian Technology Development Corporation for a $5 million private placement of Series C-1 redeemable convertible preference shares.

The purchase price of the Series C-1 preference shares is $1.55 per share and the closing is expected to occur in December 2010, WaferGen said.

MTDC has also been granted a right to purchase up to $2.5 million of Series C-2 preference shares of WaferGen's Malaysian subsidiary at a purchase price of $2.32 per share at any time within 36 months of the closing. The redeemable convertible preference shares will be converted into shares of common stock of WaferGen on a one-for-one basis within one year of issuance, the company said.

Also, the company disclosed in a recent SEC filing that it has entered into a $2 million loan agreement with Oxford Finance.

That agreement was effective Dec. 7, pursuant to a secured promissory note. The note will accrue at a fixed rate of roughly 13 percent. In connection with the loan, WaferGen issued to Oxford a warrant to purchase 95,368 shares of the firm's common stock.

The warrant is exercisable immediately at a price of $1.468 per share and expires in five years.

WaferGen, based in Fremont, Calif., said it will use the funds for general corporate purposes, including "broad commercialization of its SmartChip Real Time PCR System, which it launched in August.

Last month, WaferGen reported third-quarter revenues of $633,000, an eight-fold increase over Q3 2009 (PCR Insider, 11/18/2010). The company attributed the increase to the launch of the SmartChip system (PCR Insider, 8/5/2010).

In July, as it was preparing for the commercial launch of SmartChip, WaferGen closed a $7.2 million registered direct offering that netted the company $6.7 million (PCR Insider, 7/8/2010). The company had previously warned investors in an April prospectus that it likely would not have enough cash to continue operations through to the SmartChip launch and end of year.

WaferGen said that it finished the third quarter, ended Sept. 30, with $4.4 million in cash and cash equivalents.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.